Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017;2017:7574946.
doi: 10.1155/2017/7574946. Epub 2017 Aug 15.

Racial and Socioeconomic Disparities Are More Pronounced in Inflammatory Breast Cancer Than Other Breast Cancers

Affiliations
Free PMC article

Racial and Socioeconomic Disparities Are More Pronounced in Inflammatory Breast Cancer Than Other Breast Cancers

Ryan A Denu et al. J Cancer Epidemiol. .
Free PMC article

Abstract

Inflammatory breast cancer (IBC) is a rare yet aggressive form of breast cancer. We examined differences in patient demographics and outcomes in IBC compared to locally advanced breast cancer (LABC) and all other breast cancer patients from the Breast and Prostate Cancer Data Quality and Patterns of Care Study (POC-BP), containing information from cancer registries in seven states. Out of 7,624 cases of invasive carcinoma, IBC and LABC accounted for 2.2% (N = 170) and 4.9% (N = 375), respectively. IBC patients were more likely to have a higher number (P = 0.03) and severity (P = 0.01) of comorbidities than other breast cancer patients. Among IBC patients, a higher percentage of patients with metastatic disease versus nonmetastatic disease were black, on Medicaid, and from areas of higher poverty and more urban areas. Black and Hispanic IBC patients had worse overall and breast cancer-specific survival than white patients; moreover, IBC patients with Medicaid, patients from urban areas, and patients from areas of higher poverty and lower education had worse outcomes. These data highlight the effects of disparities in race and socioeconomic status on the incidence of IBC as well as IBC outcomes. Further work is needed to reveal the causes behind these disparities and methods to improve IBC outcomes.

Figures

Figure 1
Figure 1
All-cause overall survival (a) and breast cancer-related survival (b) among inflammatory breast cancer patients based on race and ethnicity, Patterns of Care, 2004–2012.

Similar articles

See all similar articles

Cited by 1 article

  • Survivorship and Advocacy in Inflammatory Breast Cancer.
    Alexander A, Arnold TL, Bishnoi S, Ballinger C, Shaitelman SF, Schaverien MV, Cohen L, Dev M, Ueno NT. Alexander A, et al. J Cancer. 2018 Apr 6;9(8):1430-1436. doi: 10.7150/jca.21281. eCollection 2018. J Cancer. 2018. PMID: 29721053 Free PMC article.

References

    1. Low J. A., Berman A. W., Steinberg S. M., Danforth D. N., Lippman M. E., Swain S. M. Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. Journal of Clinical Oncology. 2004;22(20):4067–4074. doi: 10.1200/JCO.2004.04.068. - DOI - PubMed
    1. Merajver S. D., Iniesta M. D., Sabel M. S. Inflammatory Breast Cancer. 4th. Philadelphia, Pa, USA: Lippincott Williams & Wilkins; 2010.
    1. Hance K. W., Anderson W. F., Devesa S. S., Young H. A., Levine P. H. Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. Journal of the National Cancer Institute. 2005;97(13):966–975. doi: 10.1093/jnci/dji172. - DOI - PMC - PubMed
    1. Wingo P. A., Jamison P. M., Young J. L., Gargiullo P. Population-based statistics for women diagnosed with inflammatory breast cancer (United States) Cancer Causes and Control. 2004;15(3):321–328. doi: 10.1023/B:CACO.0000024222.61114.18. - DOI - PubMed
    1. Anderson W. F., Schairer C., Chen B. E., Hance K. W., Levine P. H. Epidemiology of inflammatory breast cancer (IBC) Breast Disease. 2005;22:9–23. doi: 10.3233/BD-2006-22103. - DOI - PMC - PubMed

LinkOut - more resources

Feedback